HIV-1 replication can be inhibited by type I interferon (IFN), and the expression of a number of gene products with anti-HIV-1 activity is induced by type I IFN 1, 2 . However, none of the known antiretroviral proteins can account for the ability of type I IFN to inhibit early, preintegration phases of the HIV-1 replication cycle in human cells 3, 4 . Here, by comparing gene expression profiles in cell lines that differ in their ability to support the inhibitory action of IFN-a at early steps of the HIV-1 replication cycle, we identify myxovirus resistance 2 (MX2) as an interferon-induced inhibitor of HIV-1 infection. Expression of MX2 reduces permissiveness to a variety of lentiviruses, whereas depletion of MX2 using RNA interference reduces the anti-HIV-1 potency of IFN-a. HIV-1 reverse transcription proceeds normally in MX2-expressing cells, but 2-long terminal repeat circular forms of HIV-1 DNA are less abundant, suggesting that MX2 inhibits HIV-1 nuclear import, or destabilizes nuclear HIV-1 DNA. Consistent with this notion, mutations in the HIV-1 capsid protein that are known, or suspected, to alter the nuclear import pathways used by HIV-1 confer resistance to MX2, whereas preventing cell division increases MX2 potency. Overall, these findings indicate that MX2 is an effector of the anti-HIV-1 activity of type-I IFN, and suggest that MX2 inhibits HIV-1 infection by inhibiting capsid-dependent nuclear import of subviral complexes.
We and others have previously identified proteins with antiretroviral activity on the basis of their differential expression in cells that are permissive or non-permissive with respect to particular steps in the HIV-1 life cycle 5, 6 . We noticed that monocytoid cell lines varied in their ability to support the anti-HIV-1 activity of type I IFN. Specifically, IFN-a treatment of THP-1 cells caused an ,40-fold reduction in infection by an HIV-1-based green fluorescent protein (GFP) reporter vector, whereas treatment of K562 and U937 cells had little effect (Fig. 1a) . When these cell lines were differentiated into a macrophagelike state by treatment with phorbol 12-myristate 13-acetate (PMA), the inhibitory effect of IFN-a was accentuated in THP-1 cells and accentuated to a lesser extent in U937 cells, but remained nearly absent in K562 cells (Fig. 1a) .
To identify candidate effectors of the antiviral action of IFN-a, we used microarrays to measure messenger RNA levels in the aforementioned cell lines. Twenty-two genes whose induction, or non-induction, by IFN-a correlated to varying degrees with the ability or inability of IFN-a to inhibit HIV-1-GFP vector infection in the monocytoid cell lines were selected for further study (Fig. 1b and Extended Data Figs 1 and 2 ). Among these candidates, MX2, a gene that was not previously thought to exhibit antiviral activity 7 , was of particular interest as we recently identified it as a 'hit' in an overexpression screen in a T-cell line during which MX2 modestly inhibited infection by HIV-1 (ref. 8) . Western blot analyses confirmed that MX2 expression was strongly induced by IFN-a in THP-1 cells but not K562 cells, and a basal level of MX2 expression was slightly increased by IFN-a treatment in U937 cells (Fig. 1c) . MX2 was expressed at a basal level in primary CD4
1 T cells and macrophages, and was induced to varying degrees by IFN-a, depending on the individual donor, and how cells were activated (Extended Data Fig. 3) .
Expression of the 22 candidate and control genes in K562 cells revealed that only MX2 and a control antiviral gene coding for rhesus macaque TRIM5-a 9 inhibited HIV-1 infection. (Fig. 2a) . A rhesus macaque variant of MX2 also inhibited HIV-1 infection to a similar degree as human MX2, whereas MX1 was inactive against HIV-1 (Fig. 2a) , even though it inhibits a variety of other viruses 7 . Although MX2 clearly inhibited HIV-1 infection (Fig. 2a-d) , the fact that U937 cells (Fig. 1a) , primary macrophages and anti-CD3/CD28-stimulated CD4
1 T cells are readily infected by HIV-1, despite expressing appreciable levels of MX2 ( Fig. 1c and Extended Data Fig. 3 ), indicates that the block imposed by MX2 is not absolute, or that MX2 potency is perhaps influenced by the cellular environment or cofactors.
MX1 and MX2 are members of a family of dynamin-like GTPases 7 , but only MX2 is localized to the nucleus by virtue of a basic nuclear localization signal (NLS) contained within its amino-terminal 25 amino acids 10, 11 . Notably, the N-terminal 25 amino acids that encode the MX2 NLS were strictly required for antiviral activity (Fig. 2b, c) . Conversely, the mutations K131A and T151A-which inhibit GTP binding and hydrolysis, respectively 11 -did not block the anti-HIV-1 activity of MX2 (Fig. 2b, c) . This result is in contrast to findings with MX1, whose antiviral activity is GTPase dependent 7 , but should be interpreted cautiously given the reported ability of these MX2 mutants to induce a generalized perturbation of nucleocytoplasmic transport 11 . In addition to its activity against HIV-1 and HIV-2 ( Fig. 2d) , MX2 expression in HOS cells inhibited infection by GFP reporter viruses based on a variety of primate lentiviruses, including simian immunodeficiency viruses SIV MAC , SIV AGM Tan and SIV AGM Sab, with some variation in MX2 antiviral potency (Fig. 2e) . The nonprimate lentiviruses-equine infectious anaemia virus and feline immunodeficiency virus-were less potently inhibited, whereas a gammaretrovirus-murine leukaemia virus-was only marginally sensitive to MX2.
The experiments described above all represented single-cycle infection assays, using vesicular stomatitis virus glycoprotein (VSV-G) -pseudotyped reporter viruses. However, expression of MX2 in GHOST-R5 cells also inhibited infection by two full-length primary HIV-1 strains, suggesting that MX2 inhibition was independent of the route of entry, and not counteracted by HIV-1 accessory genes (Fig. 3a) . Moreover, MX2 expression in GHOST-X4 cells inhibited spreading infection by full-length replication-competent HIV-1 NL4-3 ( Fig. 3b) , reducing the number of infected cells by ,20-fold during the exponential phase of viral growth. Reduction of MX2 expression in THP-1 cells (Fig. 3c, d ) or in HOS cells (Extended Data Fig. 4a , b) using short hairpin RNAs (shRNAs) reduced, but did not eliminate, the antiviral effect of IFN-a. Thus, MX2 is required for the full potency of IFN-a, but is not solely responsible for the inhibitory action of IFN-a on the early steps of the HIV-1 replication cycle.
Consistent with this conclusion, IFN-a treatment reduced the accumulation of HIV-1 reverse transcripts in HOS cells (Fig. 4a) , as has previously been reported for other cell types 12 . Conversely, MX2 expression did not inhibit reverse transcript accumulation in either HOS or K562 cells ( , we found that that N-or carboxy-terminally haemagglutinintagged forms of MX2 were particularly concentrated at nuclear pores marked by the nucleoporin NUP98 (Extended Data Fig. 6 ). The MX2(K131A) mutant is primarily cytoplasmic but nevertheless inhibits nucleocytoplasmic transport 11 and also retains antiviral activity (Fig. 2c) . Therefore, alteration of the fate of incoming HIV-1 DNA with respect to the nucleus may underlie the antiviral activity of MX2, even though stable physical association with nuclear pores may not be required for antiviral function.
The HIV-1 capsid protein (CA) is a key determinant required for infection of non-dividing cells and nuclear entry of subviral complexes [13] [14] [15] . Indeed, HIV-1 CA mutations have been shown to change the requirement for specific nucleoporins (for example, NUP358 (also known as RANBP2), NUP85, NUP153, NUP155) during HIV-1 infection, and to alter the distribution of sites at which HIV-1 DNA integrates into host chromosomes [16] [17] [18] . Therefore, we tested whether a number of CA mutations that are known or suspected to affect the pathway used by HIV-1 DNA into the nucleus also affected sensitivity to inhibition by MX2 (Fig. 4b) . Of these, a mutation (N57S) that confers cell cycle dependence on HIV-1 infection 19 , and presumably restricts HIV-1 nuclear entry to the mitotic phase of the cell cycle, conferred resistance Titre (IU ml 
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to MX2 (Fig. 4b) . Another mutation, G89V, which abolishes cyclophilin A binding by HIV-1 CA and the requirement for NUP358 during HIV-1 infection 17 , also conferred apparently complete MX2 resistance (Fig. 4b) . Another CA mutation, N74D, which abolishes CA interaction with cleavage and polyadenylation specificity factor 6 (CPSF6) 16 , reduced but did not eliminate sensitivity to MX2, whereas the mutations G94D and A92E, which confer cyclophilin A sensitivity (cyclosporin A dependence) during early replication steps 20 , slightly reduced MX2 sensitivity (Fig. 4b ). These data demonstrate that the viral capsid governs the sensitivity of HIV-1 to MX2. In addition, they show that the antiviral activity of MX2 is specific, and unlikely to be the result of some generalized perturbation of cell physiology. Notably, the MX2-resistant CA mutant N57S exhibited a modest degree of resistance to IFN-a, relative to wild-type HIV-1, in THP-1 cells and HOS cells (Fig. 4c and Extended Data Fig. 7) , supporting the notion that MX2 is one, but not the only, effector of the antiviral activity of IFN-a during the early steps of the HIV-1 replication cycle.
Because the cell-cycle-dependent HIV-1 CA mutant N57S was not inhibited by MX2 (Fig. 4b) , we reasoned that arresting the cell cycle and thereby restricting HIV-1 infection to non-mitotic cells might potentiate the antiviral activity of MX2. Growth arrest of HOS or K562 cells with aphidicolin blocked infection by a control cell-cycledependent retrovirus (murine leukaemia virus) irrespective of MX2 expression, whereas HIV-1 was almost unaffected, as expected ( Fig. 4d and Extended Data Fig. 8a, b) . However, the inhibitory activity of MX2 was increased in non-dividing cells (Fig. 4d and Extended Data Fig. 8 ), in which it inhibited a single cycle of replication by ,30-fold. In other words, MX2 both inhibited and conferred a degree of cell cycle dependence on wild-type HIV-1 infection.
Type I IFN inhibits HIV-1 replication at multiple points in the life cycle, both before and after the point at which MX2 seems to act 2, 6, 12 .
Thus MX2 is one of multiple effectors that contribute to the overall anti-HIV-1 activity of type I IFN. A few potential mechanisms might underlie the anti-HIV-1 activity of MX2. First, MX2 might directly target the incoming viral capsid, in a manner akin to the primate TRIM5-a and murine Fv1 antiretroviral proteins 2, 9, 21 , or mutant cytoplasmic forms of CPSF6 (ref. 16 ). As with MX2, one consequence of the action of these capsid-targeting proteins is inhibition of the import of viral DNA into the nucleus, and in some cases their potency is enhanced in non-dividing cells 16, 22 . A second possibility is that MX2 inhibits particular nuclear import pathways, without regard to the precise nature of the import cargo, as mutant forms of MX2 have been shown to inhibit the nuclear accumulation of model cargos unrelated to HIV-1 (ref. 11). A third possibility is that MX2 acts after nuclear entry to destabilize viral DNA and/or inhibit integration. In these scenarios, CA mutations (G89V, N57S) could confer resistance by inhibiting interaction with MX2, by modulating the timing or extent of capsid uncoating, or by directing HIV-1 to alternative nuclear entry pathways. We note that the MX2-resistant G89V and N57S mutants exhibit reduced infectiousness in human cells, raising the possibility that the mutations abolish the use of pathways or processes during infection that are inhibited by MX2. Finally, it is possible that MX2 acts indirectly, for example by affecting the nuclear-cytoplasmic distribution of other cellular proteins that can interact with the viral capsid. However, the poor correlation in the degree of MX2 (Fig. 4) and CPSF6 
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Gene expression in monocytoid cell lines was measured using human HT12 Expression Beadchip (Illumina) containing ,48,000 transcript probes, according to the manufacturer's instructions. Candidate antiviral genes, MX2 and MX2 mutants were expressed in K562, HOS or GHOST cells using the HIV-1-based vectors SCRPSY (which encodes TagRFP and puromycin resistance) or CSIB (which confers blasticidin resistance). MX2-and control-vector-expressing cells were used as populations or as single-cell clones in infection assays to evaluate MX2 antiviral activity. All single-cycle GFP reporter viruses were pseudotyped with VSV-G. Virus stocks were generated by transfecting 293T cells with Env-defective proviral DNA that encoded GFP in place of the nef gene, or in the case of primary HIV-1 strains, full-length proviral plasmids. Alternatively, packageable GFP-expressing retroviral vector and Gag-Pol packaging plasmids were cotransfected. Target cells in microwell plates were challenged with various doses of virus and single-cycle replication evaluated after 2 days. The proportion of cells infected with GFP reporter viruses, or replication-competent virus infection in GHOST cells (which contain an LTR-GFP indicator gene) in single cycle or spreading replication assays was measured by flow cytometry. MX2 expression was reduced in target cells using a modified lentiviral shRNA expression vector (Origene). Non-dividing target cells were generated by aphidicolin treatment for 24 h before and during infection.
The abundance of viral DNA species was measured using quantitative PCR with primers directed to the GFP reporter gene, or to viral LTR sequences that are proximate only in 2-LTR circles. Western blotting was done using fluorescent antibodies and signals quantitated with a LI-COR Odyssey scanner. Deconvolution microscopy and image analysis was done using a Deltavision microcopy suite.
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